OBJECTIVES: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder prevalent in up to 35% of the adult population in Mexico, thus rendering high costs for health institutions. Tegaserod, a 5-HT4 receptor agonist approved for the treatment of IBS, could potentially render a benefi cial economic impact. An economic evaluation was performed to assess the economic impact of treating IBS patients with tegaserod in comparison to standard therapy in an institutional setting in Mexico. METHODS: A cost-effectiveness analysis was performed within an institutional setting (Mexican Institute of Social Security, IMSS). The drug comparator used was butylhyoscine, as it is the recommended standard therapy available in the National Formulary, as published in the institution's IBS clinical guidelines. Resource utilization data was obtained from previous studies; physician consults, drug usage, laboratory tests, endoscopic procedures, non-endoscopic diagnostic procedures, and surgical procedures were used for the analysis; a triangular probability distribution was used. Efficacy data was obtained from published meta-analysis studies. The source of the unit costs was the institution, current for 2009. Discount rate was not used because the time horizon was for 1 year. a probabilistic sensibility analysis was obtained through a Monte Carlo simulation with 100,000 iterations in the weakest parameters.
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COST-EFFECTIVENESS OF SEROLOGIC TESTING FOR DIAGNOSING CELIAC DISEASE
Chandra KM 1 , Costa V 2 , Blackhouse G 1 , Goeree R 1 1 McMaster University, Hamilton, ON, Canada; 2 Ministry of Health and Long-Term Care, Toronto, ON, Canada OBJECTIVES: To assess the cost-effectiveness of tests for diagnosing celiac disease (CD). The following tests were assessed: biopsy; endomysial antibody (EMA); antigliadin antibody (AGA); deaminated gliadin peptide (DGP); tissue transglutaminase (TTG); and panel of tests. METHODS: A decision analysis was constructed to compare costs and outcomes based on sensitivity, specifi city and prevalence estimates from a primary systematic literature review. Study results were pooled using a bivariate, binomial, generalized linear mixed model (SAS 9.2). The target population was adults and children experiencing symptoms consistent with CD. Biopsy was assumed to have sensitivity and specifi city of 1 since it is considered the gold standard. In serologic testing strategies the positive cases (true or false) were assumed to be confi rmed with biopsy. a family physician consult was incurred with serologic testing and a gastroenterologist consult was incurred with biopsy. The outcome of the analysis was expected costs and false negatives (FN). Costs were reported in 2010 CAD$. All analyses were performed using TreeAge Pro Suite 2009. RESULTS: Four strategies made up the effi ciency frontier; IgGTTG, IgATTG, EMA and biopsy. All other strategies were either strictly or extendedly dominated. IgGTTG was the least costly and least effective strategy ($178.95, 0.1553 FNs) . Biopsy was the most costly and most effective strategy ($396.60, 0 FNs) . The cost per FN avoided moving from IgGTTG to the other strategies sequentially on the effi ciency frontier were $293, $369, $1401 for EMA, IgATTG and biopsy respectively. One-way sensitivity analyses did not change the ranking of strategies. CONCLUSIONS: All testing strategies with biopsy were cheaper than biopsy alone however they also resulted in more FNs. If a decision maker's willingness to pay to avoid a FN result is $1401 or greater, then biopsy alone is the most cost-effective strategy. Otherwise, either IgGTTG, IgATTG or EMA is the most cost-effective strategy. 
PGI16 COST-EFFECTIVENESS OF ON-TREATMENT MONITORING OF HBSAG LEVELS TO PREDICT RESPONSE TO PEGINTERFERON-ALPHA-2A FOR HEPATITIS B TREATMENT UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
PGI17 COULD AN INNOVATIVE SURGICAL PROCEDURE SUCH AS STAPLED HEMORRHOIDOPEXY BE COST-EFFECTIVE AND EVEN COST-SAVING IN UK CLINICAL PRACTICE?
Ribaric G 1 , Kofl er J 1 , Jayne DG 2 1 Ethicon Endo-Surgery (Europe) GmbH, Norderstedt, Germany; 2 St. James's University Hospital, Leeds, England OBJECTIVES: Stapled hemorrhoidopexy (SH) offers several benefi ts over conventional excisional hemorrhoidectomy, which makes it attractive to patients with symptomatic prolapsing piles, yet its provision remains disparate. a full economic evaluation of stapled hemorrhoidopexy was undertaken to establish its cost-effectiveness and take into consideration recent literature on clinical outcomes to show that the SH procedure can become cost-saving compared to CH (conventional hemorrhoidectomy).
METHODS:
A cost-utility analysis was undertaken to compare the use of SH with CH.The analysis used a probabilistic, cohort-based decision tree within a 1-year timehorizon. Costs were analyzed from hospital and UK NHS perspective and utility was calculated using Quality Adjusted Life-years (QALY). Sensitivity analyses were used to show how variation in the clinical parameters affects cost-effectiveness.
RESULTS:
The decrease in time in the operating theatre and shorter hospital stay with SH led to a cost saving of £27 per procedure compared to CH on a hospital level. From the NHS perspective the total treatment costs inclusive of the cost of recurrent prolapse, led to an incremental cost of £33 after one year. Calculation of QALYs induced an incremental QALY of 0.0076 and showed an ICER of £4,316, which is a highly costeffective result. Sensitivity analysis taking into account recent publications showed that the SH procedure becomes cost saving with a reduction in recurrence rate of prolapse from 10% to 5% or a 50% reduction in re-surgery rate. CONCLUSIONS: Stapled hemorrhoidopexy is a cost-effective procedure with an incremental costeffective ration (ICER) of £4136. Furthermore the analysis also showed that stapled hemorrhoidopexy could even be cost-saving in UK clinical practice. This economic analysis, in line with the 2007 NICE guidance, supports its widespread implementation.
PGI18 ECONOMICS OF A SYMPTOM BASED PATIENT MANAGEMENT APPROACH FOR GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), USING GERDQ, COMPARED TO AN INVASIVE APPROACH USING GASTROSCOPY AND PH-METRY
Jonasson C 1 , Langkilde LK 2 , Hatlebakk JG 3 1 AstraZeneca AS, Oslo, Norway; 2 Wickstrøm & Langkilde ApS, Vejle, Denmark; 3 University of Bergen, Bergen, Norway OBJECTIVES: In Norway, proton pump inhibitor (PPI) therapy for GERD can only be reimbursed for patients with a diagnosis verifi ed by gastroscopy or pH-metry. The purpose of this study (NCT00842387) was to evaluate the economic aspects of an alternative, structured treatment pathway based on GerdQ-a validated PRO tool for the diagnosis and treatment decisions in GERD. METHODS: Two treatment pathways in patients presenting with refl ux, but no alarm symptoms were evaluated in an open randomized, parallel-group 8 week study. In the New Structured Pathway (NSP) diagnosis and treatment were based on GerdQ scores dividing patients into high impact GERD (treated with esomeprazole 40 mg), medium impact GERD (treated with generic PPI) and low probability of GERD (treated at the physician's discretion). In the Ordinary Clinical Pathway (OCP), the physician was kept blinded to the GerdQ score and diagnosis was based on fi ndings at gastroscopy or, if needed, pH-metry. Treatment was given according to normal clinical practice. Direct medical cost was estimated based on diagnostic procedures, medication and unscheduled health care visits. RESULTS: Treatment success with NSP diagnostic method was not inferior to OCP. The response rates were 86.5% and 80.1%, respectively. The health economic evaluation could thus be performed as a cost-minimization analysis. More patients in the NSP arm were treated with esomeprazole 40 mg than in the OCP arm (28.4% vs. 10.2%); however, fewer health care visits and diagnostic procedures were seen. The average direct medical cost in the NSP arm was c51 per patient (NOK 410) compared with c390 (NOK 3139) in the OCP arm. CONCLUSIONS: By integrating the New Structured Pathway into clinical practice, direct health care resource use may be reduced without any loss in clinical effectiveness.
